Proteins and Peptides

3 July 2013

CSL Behring Presents Phase I Results From Study of Recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP) in Healthy Volunteers

3 July 2013

CSL Behring Presents Population Pharmacokinetic Model for Novel Recombinant Factor IX Hemophilia B Treatment That Supports Less Frequent Administration

3 July 2013

CSL Behring International Trial Shows Clinical Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) for Once Weekly Prophylaxis in Patients with Severe Hemophilia B

2 July 2013

CSL Behring Announces Results from Study of Recombinant Single-Chain Factor VIII (rVIII-SingleChain) for Treatment of Hemophilia A

2 July 2013

Biogen Idec and Sobi Present New Data from the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ALPROLIX

2 July 2013

Portola Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity of Eliquis(R)

2 July 2013

The Medicines Company Announces Positive Results for Solo II Trial of Oritavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

2 July 2013

La Jolla Pharmaceutical Company Announces FDA Acceptance of IND for LJPC-501

2 July 2013

Baxter Reports Results of ADVATE Real-World Experience from Worldwide Post-Marketing Database of Hemophilia A Patients

2 July 2013

New Coagulation Factor VIIa (Recombinant) Shows Dose Response and is Well Tolerated in Patients with Hemophilia A and B (with or without inhibitors).

2 July 2013

Celldex Therapeutics Initiates Pilot Study in Dense Deposit Disease

2 July 2013

Achillion Provides Update on Sovaprevir Development Program

1 July 2013

Preclinical Data From Biogen Idec-Amunix Partnership Presented at ISTH Congress

1 July 2013

Halozyme Presents New HTI-501 Data

1 July 2013

Takeda Announces Withdrawal of Marketing Authorization Application for Peginesatide Injection in Europe

30 June 2013

Redistribution of market shares in the hemophilia market of recombinant coagulation factors due to new approvals and differential profiles

28 June 2013

Eleven Biotherapeutics Announces Positive Topline Data on EBI-005, a Novel Topical IL-1 Inhibitor Protein Therapeutic, in Patients with Dry Eye Disease

27 June 2013

FDA Approves Baxter’s RIXUBIS as First Recombinant Factor IX Treatment for Routine Prophylaxis of Hemophilia B

27 June 2013

Karolinska Development AB (publ): Pergamum reports positive follow-up data from a Phase II clinical trial of PXL-01 for prevention of post-surgical adhesions

27 June 2013

GSK announces data from five Phase III studies of albiglutide, an investigational once-weekly treatment for type 2 diabetes

25 June 2013

Amicus Therapeutics Announces Chaperone-Advanced Replacement Therapy in Development for Mucopolysaccharidosis Type I (MPS I)

24 June 2013

Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541

24 June 2013

Zealand presents first data on novel liquid glucagon peptide agonist, showing potential to treat and/or prevent severe hypoglycemia associated with diabetes

24 June 2013

DiaMedica Advances DM-199 Phase I/II Clinical Program for Treatment of Type 2 Diabetes

24 June 2013

RegeneRx Releases Results of Phase 2 Clinical Trial on Patients with Epidermolysis Bullosa

24 June 2013

Biogen Idec Showcases Commitment to Advancing Hemophilia Treatment and Care at ISTH Congress

24 June 2013

Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes

24 June 2013

Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300

22 June 2013

Theravance Announces FDA Approval of VIBATIV(R) (telavancin) for the Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

21 June 2013

FDA grants Breakthrough Therapy designation to Novartis’ serelaxin (RLX030) for acute heart failure

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

TROP-2-Targeted Immunotherapy Pipeline Review

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

FcRn Inhibitors Pipeline Review

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review